133 related articles for article (PubMed ID: 36355617)
21. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
[TBL] [Abstract][Full Text] [Related]
22. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
24. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome.
Elsamany SA; Al-Fayea TM; Alzahrani AS; Abozeed WN; Darwish W; Farooq MU; Almadani AS; Bukhari EA
Asian Pac J Cancer Prev; 2015; 16(7):2987-91. PubMed ID: 25854394
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
26. Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.
De Dosso S; Nucifora M; Sahnane N; Epistolio S; Riveiro ME; Bertolini V; Bucci E; Boldorini R; Freguia S; Frattini M; Saletti P
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2994-3003. PubMed ID: 32271417
[TBL] [Abstract][Full Text] [Related]
27. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
28. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
30. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
Rose JS; Serna DS; Martin LK; Li X; Weatherby LM; Abdel-Misih S; Zhao W; Bekaii-Saab T
Cancer; 2012 Dec; 118(24):6243-52. PubMed ID: 22674181
[TBL] [Abstract][Full Text] [Related]
31. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
32. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N
J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638
[TBL] [Abstract][Full Text] [Related]
33. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
34. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ; Sholl LM; Aisner DL; Bunn PA; Khuri FR; Ramalingam SS
J Thorac Oncol; 2019 May; 14(5):876-889. PubMed ID: 30735816
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of dynamin-related protein 1 expression in advanced lung adenocarcinoma.
Huang YL; Chen YJ; Juan YH; Wu SG; Chung KP
Pathol Res Pract; 2022 Jun; 234():153931. PubMed ID: 35523103
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
39. Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.
Yang IS; Kim S
BMC Bioinformatics; 2018 Feb; 19(Suppl 1):40. PubMed ID: 29504894
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
Ueda D; Ito M; Tsutani Y; Giménez-Capitán A; Román-Lladó R; Pérez-Rosado A; Aguado C; Kushitani K; Miyata Y; Arihiro K; Molina-Vila MA; Rosell R; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3709-3718. PubMed ID: 33796913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]